3,349 research outputs found

    The effect of elevated carbon dioxide on the sinking and swimming of the shelled pteropod Limacina retroversa

    Get PDF
    Author Posting. © The Author(s), 2017. This is the author's version of the work. It is posted here under a nonexclusive, irrevocable, paid-up, worldwide license granted to WHOI. It is made available for personal use, not for redistribution. The definitive version was published in ICES Journal of Marine Science 74 (2017): 1893–1905, doi:10.1093/icesjms/fsx008.Shelled pteropods are planktonic molluscs that may be affected by ocean acidification. Limacina retroversa from the Gulf of Maine were used to investigate the impact of elevated carbon dioxide (CO2) on shell condition as well as swimming and sinking behaviours. Limacina retroversa were maintained at either ambient (ca. 400 μatm) or two levels of elevated CO2 (800 and 1200 μatm) for up to four weeks, and then examined for changes in shell transparency, sinking speed, and swimming behaviour assessed through a variety of metrics (e.g., speed, path tortuosity, wing beat frequency). After exposures to elevated CO2 for as little as four days, the pteropod shells were significantly darker and more opaque in the elevated CO2 treatments. Sinking speeds were significantly slower for pteropods exposed to medium and high CO2 in comparison to the ambient treatment. Swimming behaviour showed less clear patterns of response to treatment and duration of exposure, but overall, swimming did not appear to be hindered under elevated CO2. Sinking is used by L. retroversa for predator evasion, and altered speeds and increased visibility could increase the susceptibility of pteropods to predation.Funding for this research was provided by a National Science Foundation grant to Lawson, Maas, and Tarrant (OCE-1316040). Additional support for field sampling was provided by the WHOI Coastal Ocean Institute, Pickman Foundation, and the Tom Haas Fund at the New Hampshire Charitable Foundation

    Densin-180 controls the trafficking and signaling of L-type voltage-gated Ca_v 1.2 Ca^(2+) channels at excitatory synapses

    Get PDF
    Voltage-gated Ca_v1.2 and Ca_v1.3 (L-type) Ca^(2+) channels regulate neuronal excitability, synaptic plasticity, and learning and memory. Densin-180 (densin) is an excitatory synaptic protein that promotes Ca^(2+)-dependent facilitation of voltage-gated Ca_v1.3 Ca^(2+) channels in transfected cells. Mice lacking densin (densin KO) exhibit defects in synaptic plasticity, spatial memory, and increased anxiety-related behaviors --phenotypes that more closely match those in mice lacking Ca_v1.2 than Ca_v1.3. Thus, we investigated the functional impact of densin on Ca_v1.2. We report that densin is an essential regulator of Ca_v1.2 in neurons, but has distinct modulatory effects compared to its regulation of Ca_v1.3. Densin binds to the N-terminal domain of Ca_v1.2 but not Ca_v1.3, and increases Ca_v1.2 currents in transfected cells and in neurons. In transfected cells, densin accelerates the forward trafficking of Ca_v1.2 channels without affecting their endocytosis. Consistent with a role for densin in increasing the number of postsynaptic Ca_v1.2 channels, overexpression of densin increases the clustering of Ca_v1.2 in dendrites of hippocampal neurons in culture. Compared to wild-type mice, the cell-surface levels of Ca_v1.2 in the brain as well as Ca_v1.2 current density and signaling to the nucleus are reduced in neurons from densin KO mice. We conclude that densin is an essential regulator of neuronal Ca_v1 channels and ensures efficient Ca_v1.2 Ca^(2+) signaling at excitatory synapses

    Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

    Get PDF
    Neurofibromatosis type 1 (NF1), the most common tumor predisposition syndrome, occurs when NF1 gene variants result in loss of neurofibromin, a negative regulator of RAS activity. Plexiform neurofibromas (PN) are peripheral nerve sheath tumors that develop in patients with NF1 and are associated with substantial morbidity and for which, until recently, the only treatment was surgical resection. However, surgery carries several risks and a proportion of PN are considered inoperable. Understanding the genetic underpinnings of PN led to the investigation of targeted therapies as medical treatment options, and the MEK1/2 inhibitor selumetinib has shown promising efficacy in pediatric patients with NF1 and symptomatic, inoperable PN. In a phase I/II trial, most children (approximately 70%) achieved reduction in tumor volume accompanied by improvements in patient-reported outcomes (decreased tumor-related pain and improvements in quality of life, strength, and range of motion). Selumetinib is currently the only licensed medical therapy indicated for use in pediatric patients with symptomatic, inoperable NF1-PN, with approval based on the results of this pivotal clinical study. Several other MEK inhibitors (binimetinib, mirdametinib, trametinib) and the tyrosine kinase inhibitor cabozantinib are also being investigated as medical therapies for NF1-PN. Careful consideration of multiple aspects of both disease and treatments is vital to reduce morbidity and improve outcomes in patients with this complex and heterogeneous disease, and clinicians should be fully aware of the risks and benefits of available treatments. There is no single treatment pathway for patients with NF1-PN; surgery, watchful waiting, and/or medical treatment are options. Treatment should be individualized based on recommendations from a multidisciplinary team, considering the size and location of PN, effects on adjacent tissues, and patient and family preferences. This review outlines the treatment strategies currently available for patients with NF1-PN and the evidence supporting the use of MEK inhibitors, and discusses key considerations in clinical decision-making

    High Sensitivity Array Observations of the z=1.87 Sub-Millimeter Galaxy GOODS 850-3

    Full text link
    We present sensitive phase-referenced VLBI results on the radio continuum emission from the z=1.87 luminous submillimeter galaxy (SMG) GOODS 850-3. The observations were carried out at 1.4 GHz using the High Sensitivity Array (HSA). Our sensitive tapered VLBI image of GOODS 850-3 at 0.47 x 0.34 arcsec (3.9 x 2.9 kpc) resolution shows a marginally resolved continuum structure with a peak flux density of 148 \pm 38 uJy/beam, and a total flux density of 168 \pm 73 uJy, consistent with previous VLA and MERLIN measurements. The derived intrinsic brightness temperature is > 5 \pm 2 x 10^3 K. The radio continuum position of this galaxy coincides with a bright and extended near-infrared source that nearly disappears in the deep HST optical image, indicating a dusty source of nearly 9 kpc in diameter. No continuum emission is detected at the full VLBI resolution (13.2 x 7.2 mas, 111 x 61 pc), with a 4-sigma point source upper limit of 26 uJy/beam, or an upper limit to the intrinsic brightness temperature of 4.7 x 10^5 K. The extent of the observed continuum source at 1.4 GHz and the derived brightness temperature limits are consistent with the radio emission (and thus presumably the far-infrared emission) being powered by a major starburst in GOODS 850-3, with a star formation rate of ~2500 M_sun/yr. Moreover, the absence of any continuum emission at the full resolution of the VLBI observations indicates the lack of a compact radio AGN source in this z=1.87 SMG.Comment: 19 pages, 4 figures, accepted for publication in A
    • …
    corecore